Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy

Autor:	Garon, Edward B. 1, Scagliotti, Giorgio Vittorio 2, Gautschi, Oliver 3, Reck, Martin 4, Thomas, Michael 5, Iglesias Docampo, Lara 6, Kalofonos, Haralabos 7, Kim, Joo-Hang 8, Gans, Steven 9, Te Brustugun, Oddrje 10, Orlov, Sergey V. 11, Cuyun Carter, Gebra 12, Zimmermann, Annamaria H. 13, Oton, Ana B. 12, Alexandris, Ekaterine 12, Lee, Pablo 14, Wolff, Katharina 15, Stefaniak, Victoria Jennifer 12, Socinski, Mark A. 16, Pérol, Maurice 17
Zdroj:	In ESMO Open 2020 5(1)
Databáze:	ScienceDirect
Externí odkaz:	Zobrazit plný text záznamu